Table 3.
Key characteristics
| BASICS | BEST | ATTENTION | BAOCHE | |
|---|---|---|---|---|
| Date | 2011–2019 | 2015–2017 | 2021–2022 | 2016–2022 |
| Symptom onset to inclusion (hours) | 0–6 | 0–8 | 0–12 | 6–24 |
| Number screened | 424 | 288 | 507 | Data not available |
| Number of participants | 300 | 131 | 340 | 217 |
| Crossover (percentage) |
3/154 (1.9) to BMT 7/146 (4.7) to MT |
3/66 (4.5) to BMT 14/65 (21.5) to MT |
3/226 (1.3) to BMT 3/114 (2.6) to MT |
1/110 (0.9) to BMT 4/107 (3.7) to MT |
| Median NIHSS at presentation (IQR) |
Intervention: 21.9 Control: 22.1 (IQR not available) |
Intervention: 32 (18–38) Control: 26 (13–37) |
Intervention: 24 (15–35) Control: 24 (14–35) |
Intervention: 20 (14.5–29) Control: 19 (12–30) |
| Intravenous thrombolysis (%) |
Intervention: 121/154 (78.6) Control: 116/146 (79.5) |
Intervention: 18/66 (27) Control: 21/65 (32) |
Intervention: 69/226 (30.5) Control: 39/114 (34.2) |
Intervention: 15/110 (13.6) Control: 23/107 (21.5) |
| Blinding | Open-label, blinded outcome assessment | Open-label, blinded outcome assessment | Open-label, blinded outcome assessment | Open-label, blinded outcome assessment |
|
mRS (≤3) (percentage) |
Intervention: 68/154 (44.1) Control: 55/146 (37.6) |
Intervention: 28/66 (42.4) Control: 21/65 (32.3) |
Intervention: 104/226 (46) Control: 26/114 (22.8) |
Intervention: 51/110 (46.3) Control: 26/107 (24.2) |
| Mortality at day 90 (percentage) |
Intervention: 59 (38.3) Control: 63 (43.2) |
Intervention: 22 (33.3) Control: 25 (38.4) |
Intervention: 83 (36.7) Control: 63 (55.2) |
Intervention: 34 (30.9) Control: 45 (42.1) |
|
sICH (percentage) |
Intervention: 6 (4.5) Control: 1 (0.7) |
Intervention: 5 (8) Control: 0 |
Intervention: 12 (5) Control: 0 |
Intervention: 6 (8.8) Control: 1 (2.3) |
| Follow up: | 24 hrs, 90 days | 24 hrs, 90 days | 24 hrs, 90 days | 24 hrs, 90 days, 6 months, 1 year |